You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKesson
Medtronic
Baxter
Merck

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020835


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 020835 describes ACTONEL, which is a drug marketed by Apil and Warner Chilcott and is included in two NDAs. It is available from three suppliers. There are two patents protecting this drug and four Paragraph IV challenges. Additional details are available on the ACTONEL profile page.

The generic ingredient in ACTONEL is calcium carbonate; risedronate sodium. There are two hundred and eighty-two drug master file entries for this compound. Additional details are available on the calcium carbonate; risedronate sodium profile page.
Summary for 020835
Tradename:ACTONEL
Applicant:Apil
Ingredient:risedronate sodium
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 020835
Medical Subject Heading (MeSH) Categories for 020835
Suppliers and Packaging for NDA: 020835
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ACTONEL risedronate sodium TABLET;ORAL 020835 NDA Allergan, Inc. 0430-0470 0430-0470-15 30 TABLET, FILM COATED in 1 BOTTLE (0430-0470-15)
ACTONEL risedronate sodium TABLET;ORAL 020835 NDA Allergan, Inc. 0430-0471 0430-0471-15 30 TABLET, FILM COATED in 1 BOTTLE (0430-0471-15)
Paragraph IV (Patent) Challenges for 020835
Tradename Dosage Ingredient NDA Submissiondate
ACTONEL TABLET;ORAL risedronate sodium 020835 2008-08-12
ACTONEL TABLET;ORAL risedronate sodium 020835 2007-09-10
ACTONEL TABLET;ORAL risedronate sodium 020835 2007-09-07
ACTONEL TABLET;ORAL risedronate sodium 020835 2004-04-23

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength30MG
Approval Date:Mar 27, 1998TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Apr 14, 2000TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength35MG
Approval Date:May 25, 2002TE:ABRLD:Yes

Expired US Patents for NDA 020835

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil ACTONEL risedronate sodium TABLET;ORAL 020835-005 Apr 22, 2008   Start Trial   Start Trial
Apil ACTONEL risedronate sodium TABLET;ORAL 020835-003 May 25, 2002   Start Trial   Start Trial
Apil ACTONEL risedronate sodium TABLET;ORAL 020835-001 Mar 27, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Colorcon
AstraZeneca
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.